An aptamer-antibody complex (oligobody) as a novel delivery platform for targeted cancer therapies
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Heo, Kyun | - |
dc.contributor.author | Min, Sung-Won | - |
dc.contributor.author | Sung, Ho Jin | - |
dc.contributor.author | Kim, Han Gyul | - |
dc.contributor.author | Kim, Hyun Jung | - |
dc.contributor.author | Kim, Yun Hee | - |
dc.contributor.author | Choi, Beom Kyu | - |
dc.contributor.author | Han, Sewoon | - |
dc.contributor.author | Chung, Seok | - |
dc.contributor.author | Lee, Eun Sook | - |
dc.contributor.author | Chung, Junho | - |
dc.contributor.author | Kim, In-Hoo | - |
dc.date.accessioned | 2021-09-03T23:54:05Z | - |
dc.date.available | 2021-09-03T23:54:05Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016-05-10 | - |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/88662 | - |
dc.description.abstract | Aptamers have recently emerged as reliable and promising targeting agents in the field of biology. However, their therapeutic potential has yet to be completely assessed due to their poor pharmacokinetics for systemic administration. Here, we describe a novel aptamer-antibody complex, designated an "oligobody" (oligomer + antibody) that may overcome the therapeutic limitations of aptamers. To provide proof-of-principle study, we investigated the druggability of oligobody in vivo using cotinine conjugated t44-OMe aptamer, which is specific for the sequence of pegaptanib, and an anti-cotinine antibody. The antibody part of oligobody resulted in extended in vivo pharmacokinetics of the aptamer without influencing its binding affinity. Moreover, the aptamer of oligobody penetrated deeply into the tumor tissues whereas the anti-VEGF antibody did not. Finally, the systemic administration of this oligobody reduced the tumor burden in a xenograft mouse model. Together, these results suggested that our oligobody strategy may represent a novel platform for rapid, low-cost and high-throughput cancer therapy. (C) 2016 Elsevier B.V. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.subject | SOLID TUMORS | - |
dc.subject | COTININE | - |
dc.subject | AGENTS | - |
dc.subject | THERAPEUTICS | - |
dc.subject | STRATEGIES | - |
dc.subject | MOLECULES | - |
dc.subject | NICOTINE | - |
dc.subject | FUTURE | - |
dc.title | An aptamer-antibody complex (oligobody) as a novel delivery platform for targeted cancer therapies | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Chung, Seok | - |
dc.identifier.doi | 10.1016/j.jconrel.2016.03.006 | - |
dc.identifier.scopusid | 2-s2.0-84962596774 | - |
dc.identifier.wosid | 000375218900001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CONTROLLED RELEASE, v.229, pp.1 - 9 | - |
dc.relation.isPartOf | JOURNAL OF CONTROLLED RELEASE | - |
dc.citation.title | JOURNAL OF CONTROLLED RELEASE | - |
dc.citation.volume | 229 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 9 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | SOLID TUMORS | - |
dc.subject.keywordPlus | COTININE | - |
dc.subject.keywordPlus | AGENTS | - |
dc.subject.keywordPlus | THERAPEUTICS | - |
dc.subject.keywordPlus | STRATEGIES | - |
dc.subject.keywordPlus | MOLECULES | - |
dc.subject.keywordPlus | NICOTINE | - |
dc.subject.keywordPlus | FUTURE | - |
dc.subject.keywordAuthor | Aptamer | - |
dc.subject.keywordAuthor | Antibody | - |
dc.subject.keywordAuthor | Oligobody | - |
dc.subject.keywordAuthor | Cotinine | - |
dc.subject.keywordAuthor | Targeted cancer therapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.